Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma
M Höpfner, AP Sutter, A Huether, D Schuppan… - Journal of …, 2004 - Elsevier
… Gefitinib, an inhibitor of epidermal growth factor receptor tyrosine kinase (EGFR-TK), potently
suppresses the growth of … We therefore studied the antineoplastic potency of gefitinib in …
suppresses the growth of … We therefore studied the antineoplastic potency of gefitinib in …
[HTML][HTML] Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors
G Blackledge, S Averbuch - British journal of cancer, 2004 - nature.com
… cisplatin/vinorelbine alone in the first-line treatment of patients (pts) with epidermal growth
factor receptor (EGFR) positive advanced non-small-cell lung cancer (NSCLC). Proc Am Soc …
factor receptor (EGFR) positive advanced non-small-cell lung cancer (NSCLC). Proc Am Soc …
Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence
C Gridelli, F De Marinis, M Di Maio, D Cortinovis… - Lung Cancer, 2011 - Elsevier
… Gefitinib is a small molecule tyrosine kinase inhibitor of epidermal growth factor receptor (…
) obtaining objective response when treated with gefitinib harbour activating mutations in the …
) obtaining objective response when treated with gefitinib harbour activating mutations in the …
Predictive and prognostic impact of epidermal growth factor receptor mutation in non–small-cell lung cancer patients treated with gefitinib
… Mutations of epidermal growth factor receptor in the current study. Numbers in parentheses
indicate the number of patients with the mutation. Exons 18, 19, 21, and 23 were analyzed in …
indicate the number of patients with the mutation. Exons 18, 19, 21, and 23 were analyzed in …
Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non–small cell …
TY Chou, CH Chiu, LH Li, CY Hsiao, CY Tzen… - Clinical cancer …, 2005 - AACR
… Progression-free survival was calculated from the date of initiation of gefitinib to … of gefitinib
treatment to the date of death. Statistical analyses of clinical data and epidermal growth factor …
treatment to the date of death. Statistical analyses of clinical data and epidermal growth factor …
Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non–small-cell lung cancer with …
T Mitsudomi, T Kosaka, H Endoh, Y Horio… - Journal of Clinical …, 2005 - ascopubs.org
… who are candidates for surgical treatment in Japan. In our … family, including the epidermal
growth factor receptor (EGFR… including epidermal growth factor and transforming growth factor …
growth factor receptor (EGFR… including epidermal growth factor and transforming growth factor …
Gefitinib alone versus gefitinib plus chemotherapy for non–small-cell lung cancer with mutated epidermal growth factor receptor: NEJ009 study
Y Hosomi, S Morita, S Sugawara, T Kato… - Journal of Clinical …, 2020 - ascopubs.org
… of first-line epidermal growth factor receptor (EGFR) tyrosine … % of patients in the gefitinib
group did not receive subsequent … The median duration of gefitinib treatment was longer in the …
group did not receive subsequent … The median duration of gefitinib treatment was longer in the …
Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs
M Ono, M Kuwano - Clinical cancer research, 2006 - AACR
… Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome
of patients with non-small cell lung cancer treated with epidermal growth factor receptor …
of patients with non-small cell lung cancer treated with epidermal growth factor receptor …
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non–small cell lung cancer: a randomized trial
MG Kris, RB Natale, RS Herbst, TJ Lynch Jr, D Prager… - Jama, 2003 - jamanetwork.com
… These findings support the use of gefitinib for the treatment of patients with NSCLC who …
with the safety of gefitinib, justifies its use in patients previously treated with chemotherapy. …
with the safety of gefitinib, justifies its use in patients previously treated with chemotherapy. …
[HTML][HTML] Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer
HS Parra, R Cavina, F Latteri, PA Zucali… - British journal of …, 2004 - nature.com
… This subset of patients is representative of the total patient population treated with gefitinib
in our centre; baseline patient demographics are presented in Table 1. Most patients had …
in our centre; baseline patient demographics are presented in Table 1. Most patients had …
相关搜索
- epidermal growth factor receptor
- human epidermal growth factor receptor inhibitors
- sensitive epidermal growth factor receptor mutations
- epidermal growth factor hepatocellular carcinoma
- growth factor gefitinib responsiveness
- small cell lung cancer gefitinib treatment
- predictive and prognostic factor gefitinib treatment